Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Res ; 90(3): 565-575, 2021 09.
Article in English | MEDLINE | ID: mdl-33446917

ABSTRACT

BACKGROUND: Preterm infants with bronchopulmonary dysplasia (BPD) have lifelong increased risk of respiratory morbidities associated with environmental pathogen exposure and underlying mechanisms are poorly understood. The resident immune cells of the lung play vital roles in host defense. However, the effect of perinatal events associated with BPD on pulmonary-specific immune cells is not well understood. METHODS: We used a double-hit model of BPD induced by prenatal chorioamnionitis followed by postnatal hyperoxia, and performed a global transcriptome analysis of all resident pulmonary immune cells. RESULTS: We show significant up-regulation of genes involved in chemokine-mediated signaling and immune cell chemotaxis, and down-regulation of genes involved in multiple T lymphocyte functions. Multiple genes involved in T cell receptor signaling are downregulated and Cd8a gene expression remains downregulated at 2 months of age in spite of recovery in normoxia for 6 weeks. Furthermore, the proportion of CD8a+CD3+ pulmonary immune cells is decreased. CONCLUSIONS: Our study has highlighted that perinatal lung inflammation in a double-hit model of BPD results in short- and long-term dysregulation of genes associated with the pulmonary T cell receptor signaling pathway, which may contribute to increased environmental pathogen-associated respiratory morbidities seen in children and adults with BPD. IMPACT: In a translationally relevant double-hit model of BPD induced by chorioamnionitis and postnatal hyperoxia, we identified pulmonary immune cell-specific transcriptomic changes and showed that T cell receptor signaling genes are downregulated in short term and long term. This is the first comprehensive report delineating transcriptomic changes in resident immune cells of the lung in a translationally relevant double-hit model of BPD. Our study identifies novel resident pulmonary immune cell-specific targets for potential therapeutic modulation to improve short- and long-term respiratory health of preterm infants with BPD.


Subject(s)
Bronchopulmonary Dysplasia/genetics , Chorioamnionitis/pathology , Hyperoxia/complications , Lung/immunology , Transcriptome , Animals , Bronchopulmonary Dysplasia/etiology , Disease Models, Animal , Female , Humans , Infant, Newborn , Infant, Premature , Pregnancy , Rats , Rats, Sprague-Dawley
2.
Sci Rep ; 10(1): 20730, 2020 11 26.
Article in English | MEDLINE | ID: mdl-33244048

ABSTRACT

Pulmonary function testing (PFT) is an important component for evaluating the outcome of experimental rodent models of respiratory diseases. Respiratory inductance plethysmography (RIP) provides a noninvasive method of PFT requiring minimal cooperation. RIP measures work of breathing (WOB) indices including phase angle (Ф), percent rib cage (RC %), breaths per minute (BPM), and labored breathing index (LBI) on an iPad. The aim of this study was to evaluate the utility of a recently developed research instrument, pneuRIP, for evaluation of WOB indices in a developmental rat model. Sprague Dawley rats (2 months old) were commercially acquired and anaesthetised with isoflurane. The pneuRIP system uses two elastic bands: one band (RC) placed around the rib cage under the upper armpit and another band (AB) around the abdomen. The typical thoracoabdominal motion (TAM) plot showed the abdomen and rib cage motion in synchrony. The plots of phase angle and LBI as a function of data point number showed that values were within the range. The distribution for phase angle and LBI was within a narrow range. pneuRIP testing provided instantaneous PFT results. This study demonstrated the utility of RIP as a rapid, noninvasive approach for evaluating treatment interventions in the rodent model.


Subject(s)
Plethysmography/methods , Work of Breathing/physiology , Abdomen/physiology , Animals , Child , Humans , Infant , Isoflurane/administration & dosage , Lung/drug effects , Lung/physiology , Models, Animal , Movement/drug effects , Movement/physiology , Rats , Rats, Sprague-Dawley , Respiration/drug effects , Respiratory Function Tests/methods , Respiratory Mechanics/drug effects , Respiratory Mechanics/physiology , Work of Breathing/drug effects
3.
Pediatr Res ; 86(5): 579-588, 2019 11.
Article in English | MEDLINE | ID: mdl-31390652

ABSTRACT

BACKGROUND: Hyperoxia-induced acute lung injury (HALI) is characterized by increased permeability and infiltration of inflammatory cells, impairment of alveolar development, and compromised lung function. Recent evidence has determined that microRNAs (miRs) are implicated in hyperoxia-induced lung injury, including bronchopulmonary dysplasia (BPD). However, the expression profile and functional role of miR199a-5p in developing lungs have not been reported. METHODS: The present study was undertaken to explore the role of miR199a-5p in developing mice lungs and human neonates. We exposed neonatal mice for 7 days, mouse lung epithelial cells (MLE12), mouse lung endothelial cells (MLECs), and macrophages (RAW246.7), to hyperoxia at different time points. RESULTS: Our results demonstrated enhanced miR199a-5p expression in hyperoxia-exposed mice lungs and cells, as well as in tracheal aspirates of infants developing BPD, with significant reduction in the expression of its target, caveolin-1. Next, we observed that miR199a-5p-mimic worsens HALI as evidenced by increased inflammatory cells, cytokines, and lung vascular markers. Conversely, miR199a-5p-inhibitor treatment attenuated HALI. CONCLUSION: Thus, our findings suggest that miR199a-5p is a potential target for attenuating HALI pathophysiology in the developing lung. Moreover, miR199a-5p-inhibitor could be part of a novel therapeutic strategy for improving BPD in preterm neonates.


Subject(s)
Bronchopulmonary Dysplasia/etiology , Gene Expression Profiling , Hyperoxia/complications , Lung/growth & development , MicroRNAs/physiology , Animals , Bronchopulmonary Dysplasia/genetics , Capillary Permeability , Female , Humans , Infant, Newborn , Lung/blood supply , Male , Mice , Mice, Inbred C57BL , MicroRNAs/genetics , RAW 264.7 Cells
4.
Article in English | MEDLINE | ID: mdl-31186149

ABSTRACT

BACKGROUND: Inflammation and vaso-occlusion play key roles in Sickle Cell Disease (SCD) pathophysiology. Lipoxygenase products of the omega-3 fatty acids (O3FAs), docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids, are potent anti-inflammatory mediators modulating pain. O3FAs decrease episodes of vaso-occlusion in SCD. METHODS: We assessed erythrocyte fatty acid composition in two major cell membrane phospholipids, phosphatidylcholine and phosphatidylethanolamine, in children with SCD HbSS-disease (n = 38) and age/race-matched HbAA-controls (n = 18). Ratio of pro-inflammatory arachidonic acid (AA) to anti-inflammatory DHA and EPA (FA-Ratio), and its relationship to hs-CRP were evaluated. RESULTS: FA-Ratios were increased in both phosphatidylcholine and phosphatidylethanolamine in HbSS compared to controls. Correlations were noted in HbSS subjects between hs-CRP and FA-Ratios (p = 0.011). FA-Ratios increased with age (p = 0.0007) due to an increase in pro-inflammatory AA with a concomitant decrease in anti-inflammatory DHA. CONCLUSIONS: Findings demonstrate relative deficiencies in HbSS of the anti-inflammatory precursor fatty acids DHA and EPA, which correlates positively with hs-CRP.


Subject(s)
Anemia, Sickle Cell/blood , Biomarkers/blood , C-Reactive Protein/metabolism , Docosahexaenoic Acids/blood , Eicosapentaenoic Acid/blood , Fatty Acids, Omega-3/blood , Inflammation/blood , Adolescent , Anemia, Sickle Cell/diagnosis , Arachidonic Acid/blood , Child , Child, Preschool , Erythrocytes/metabolism , Humans , Phosphatidylcholines/blood , Phosphatidylethanolamines/blood , Risk Factors
5.
Blood ; 111(2): 905-14, 2008 Jan 15.
Article in English | MEDLINE | ID: mdl-17911385

ABSTRACT

Phosphatidylserine (PS)-positive erythrocytes adhere to endothelium and subendothelial matrix components. While thrombospondin mediates these inter-actions, it is unknown whether PS-associated erythrocyte-endothelial adhesion occurs in the absence of plasma ligands. Using ionophore-treated PS-expressing control HbAA erythrocytes, we demonstrate that PS-positive erythrocytes adhered to human lung microendothelial cells in the absence of plasma ligands, that this adhesion was enhanced following endothelial activation with IL-1alpha, TNF-alpha, LPS, hypoxia, and heme, and that this adhesive interaction was selective to erythrocyte PS. We next explored whether microendothelial cells express an adhesion receptor that recognizes cell surface-expressed PS (PSR) similar to that expressed on activated macrophages. We demonstrate constitutive expression of both PSR mRNA and protein that were up-regulated in a time-dependent manner following endothelial activation. While minimal PSR expression was noted on unstimulated cells, endothelial activation up-regulated PSR surface expression. In antibody-blocking studies, using PS-positive erythrocytes generated either artificially via ionophore treatment of control erythrocytes or from patients with sickle cell disease, we demonstrate that PSR was functional, supporting PS-mediated erythrocyte adhesion to activated endothelium. Our results demonstrate the existence of a novel functional adhesion receptor for PS on the microendothelium that is up-regulated by such pathologically relevant agonists as hypoxia, cytokines, and heme.


Subject(s)
Endothelial Cells/metabolism , Erythrocytes/metabolism , Lung/metabolism , Phosphatidylserines/metabolism , Receptors, Cell Surface/biosynthesis , Up-Regulation/physiology , Adult , Cell Adhesion/physiology , Cell Hypoxia/drug effects , Cell Hypoxia/physiology , Cells, Cultured , Endothelial Cells/cytology , Erythrocytes/cytology , Extracellular Matrix/metabolism , Female , Heme/pharmacology , Hemoglobin A/metabolism , Humans , Interleukin-1alpha/pharmacology , Ionophores/pharmacology , Ligands , Lipopolysaccharides/pharmacology , Lung/blood supply , Lung/cytology , Macrophage Activation/drug effects , Macrophage Activation/physiology , Macrophages/cytology , Macrophages/metabolism , Male , Microcirculation/metabolism , Phosphatidylserines/antagonists & inhibitors , RNA, Messenger/biosynthesis , Receptors, Cell Surface/agonists , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...